Becton, Dickinson and Company (NYSE:BDX) Given Average Recommendation of “Hold” by Brokerages

Becton, Dickinson and Company (NYSE:BDX) has received an average recommendation of “Hold” from the seventeen ratings firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $185.6667.

Several analysts have issued reports on the stock. Stifel Nicolaus set a $195.00 price target on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. UBS Group began coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They set a “buy” rating and a $190.00 price objective on the stock. Bank of America dropped their target price on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Barclays raised their target price on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research report on Friday, August 7th.

Becton, Dickinson and Company Trading Up 0.1%

Becton, Dickinson and Company stock opened at $189.71 on Monday. The firm has a 50-day moving average of $166.14 and a 200-day moving average of $160.20. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $193.07. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The company has a market cap of $52.27 billion, a price-to-earnings ratio of 57.14, a P/E/G ratio of 13.36 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The business had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the previous year, the business earned $3.68 earnings per share. Becton, Dickinson and Company’s quarterly revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities analysts expect that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is currently 126.51%.

Insiders Place Their Bets

In related news, EVP Michael Feld sold 165 shares of the stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president owned 19,720 shares in the company, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the sale, the executive vice president directly owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This represents a 14.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 9,105 shares of company stock valued at $1,590,208 over the last 90 days. 0.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BDX. Imprint Wealth LLC acquired a new stake in Becton, Dickinson and Company during the third quarter worth approximately $25,000. SHP Wealth Management acquired a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at approximately $26,000. Meeder Asset Management Inc. grew its position in shares of Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 102 shares during the last quarter. Main Street Group LTD bought a new position in shares of Becton, Dickinson and Company during the first quarter worth approximately $29,000. Finally, Bell Investment Advisors Inc acquired a new stake in Becton, Dickinson and Company during the 2nd quarter worth approximately $29,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.